本文選題：第四季度　切入點(diǎn)：治療新藥　出處：《中國(guó)藥科大學(xué)學(xué)報(bào)》2015年06期

【摘要】：正美國(guó)Merrimack公司研發(fā)的胰腺癌治療新藥MM-398有望通過美國(guó)FDA批準(zhǔn)上市;羅氏公司研發(fā)的多發(fā)性硬化癥治療新藥Ocrelizumab即將宣布Ⅲ期臨床試驗(yàn)數(shù)據(jù);阿斯利康公司研發(fā)的風(fēng)濕性關(guān)節(jié)炎治療新藥Mavrilimumab也即將宣布Ⅱ臨床試驗(yàn)數(shù)據(jù)。1.2015年第四季度有望上市的胰腺癌新藥MM-398
[Abstract]:MM-398, a new pancreatic cancer drug developed by Merrimack, is expected to be approved by FDA in the United States. Ocrelizumab, a new drug for multiple sclerosis, developed by Roche, is about to announce phase III clinical trial data.Mavrilimumab, a new rheumatoid arthritis drug developed by AstraZeneca, is also about to announce clinical trial data for 鈪，

本文編號(hào)：1714573